Where does Kevin Starr work?

Kevin Starr is Board director at Myokardia and Board director at Global Blood Therapeutics and Board director at Sage Therapeutics.

What does Kevin Starr invest in?

Kevin Starr invests in Biotech, Healthtech, Medical Devices.

What check size does Kevin Starr write?

Kevin Starr typically writes checks of $100K – $5M.

What boards does Kevin Starr sit on?

Kevin Starr holds tracked board seats at Afferent Pharmaceuticals, Decibel Therapeutics, Global Blood Therapeutics, Myokardia, Sage Therapeutics.

Where did Kevin Starr go to school?

Kevin Starr studied at Colby College (BS/BA, Mathematics, Business); Boston College Carroll School of Management (MSF, Finance).

Kevin Starr

Investor

Board director at Myokardia · Board director at Global Blood Therapeutics · Board director at Sage Therapeutics · Former Retired Founding Partner at Third Rock Ventures

Boston, Massachusetts, United States

Writes $100K – $5M checks

Find your path to Kevin

460 people in our graph can introduce you to Kevin.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Andrew Perlman to introduce you to Kevin

You →Andrew · together at Zafgen (2008–2010) →Kevin

Ask Jamie Chen to introduce you to Kevin

You →Jamie · together at Zafgen →Kevin

Ask Sam Okafor to introduce you to Kevin

You →Sam · 3 people · together at Sage Therapeutics →Kevin

Your email: the people you already email who know Kevin
2nd- and 3rd-degree connections: people you know who worked, studied or invested with Kevin
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

About

Kevin Starr co-architected a company-creation-first model that incubates academic science through 1–3-year scientist collaborations, building companies focused on ultra-rare and orphan diseases using gene therapy and precision oncology.

Invests in

BiotechHealthtechMedical Devices

Board director at Myokardia

Intro paths

→

In turn, Kevin can intro founders to Myokardia's investors below.

Myokardia's investors · 4

Avoro Capital AdvisorsNew York Foresite CapitalWest Hollywood · since 2015 Khosla VenturesMenlo Park · $100K – $20M checks · since 2015 Third Rock VenturesBoston · $100K – $5M checks · since 2015

Board director at Global Blood Therapeutics

Intro paths

→

In turn, Kevin can intro founders to Global Blood Therapeutics's investors below.

Global Blood Therapeutics's investors · 5

Aisling CapitalNew York Avoro Capital AdvisorsNew York RA CapitalBoston · since 2014 Ridgeback CapitalNew York · since 2014 Third Rock VenturesBoston · $100K – $5M checks · since 2014

Board director at Sage Therapeutics

Intro paths

→

In turn, Kevin can intro founders to Sage Therapeutics's investors below.

Sage Therapeutics's investors · 2

ARCH Venture PartnersChicago · $50K – $250M checks Third Rock VenturesBoston · $100K – $5M checks · since 2020

Experience

Sage TherapeuticsBoard Member, Start-Up CEO2011 — 2024Cambridge, MA
Third Rock VenturesRetired Partner2007 — 2021Boston, MA
Decibel TherapeuticsBoard Member, start-up CEO2015 — 2018cambridge, ma
Alnylam PharmaceuticalsBoard Member2003 — 2018
MyoKardiaBoard Member2012 — 2018San Francisco Bay Area
PanOpticaBoard member2011 — 2018New Jersey
Globalblood TherapeuticsBoard Member2012 — 2016San Francisco Bay Area
Afferent PharmaceuticalsBoard Member2009 — 2016San Mateo, CA
ZafgenBoard Member, Start-up CEO2008 — 2015Cambridge, MA
AgiosBoard Member, start-up CEO2008 — 2015
Prospect PicturesInvestor2003 — 2010
Human Genome SciencesBoard Member2005 — 2007
Vitae PharmaceuticalsBoard member2002 — 2007
Cambridge Savings Bank & Appleton Partners, Inc.Executive Committee and Board member1998 — 2007
Millennium PharmaceuticalsCOO & CFO1998 — 2003
BiogenCorporate Controller1991 — 1998
Digital Equipment CorporationBusiness/Finance1984 — 1991

Skills & more

LifesciencesPharmaceutical Industry

From Kevin's professional profile.

Deals · 4

Sage TherapeuticsBoard seat

via Third Rock Ventures · filed Jan 2021 · $650M raise

Afferent PharmaceuticalsBoard seat

via Third Rock Ventures · filed Jul 2015 · $55M raise

MyokardiaBoard seat

via Third Rock Ventures · filed Apr 2015 · $46M raise

Global Blood TherapeuticsBoard seat

via Third Rock Ventures · filed Jan 2015 · $48M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Decibel Therapeutics

Per SEC Form D filings.

Leave your own feedback

Frequently asked questions

Who is Kevin Starr?: Kevin Starr co-architected a company-creation-first model that incubates academic science through 1–3-year scientist collaborations, building companies focused on ultra-rare and orphan diseases using gene therapy and precision oncology.
Where does Kevin Starr work?: Kevin Starr is Board director at Myokardia and Board director at Global Blood Therapeutics and Board director at Sage Therapeutics.
What does Kevin Starr invest in?: Kevin Starr invests in Biotech, Healthtech, Medical Devices.
What check size does Kevin Starr write?: Kevin Starr typically writes checks of $100K – $5M.
What boards does Kevin Starr sit on?: Kevin Starr holds tracked board seats at Afferent Pharmaceuticals, Decibel Therapeutics, Global Blood Therapeutics, Myokardia, Sage Therapeutics.
Where did Kevin Starr go to school?: Kevin Starr studied at Colby College (BS/BA, Mathematics, Business); Boston College Carroll School of Management (MSF, Finance).